Activity of rapamycin (AY-22,989) against transplanted tumors
| Autor: | S. N. Sehgal, C. P. Eng, Claude Vezina |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
Male
medicine.medical_specialty Cyclophosphamide Mice Inbred Strains Polyenes Pharmacology Mice Oral administration Internal medicine Antineoplastic Combined Chemotherapy Protocols Drug Discovery Ascites medicine Animals Tumor growth Solid tumor Sirolimus Antibiotics Antineoplastic business.industry Neoplasms Experimental Melanocarcinoma medicine.disease Sequential treatment digestive system diseases Leukemia Endocrinology Colonic Neoplasms medicine.symptom business medicine.drug |
| Zdroj: | The Journal of Antibiotics. 37:1231-1237 |
| ISSN: | 1881-1469 0021-8820 |
| DOI: | 10.7164/antibiotics.37.1231 |
| Popis: | Rapamycin exhibits activity against several ascites and solid transplantable tumors; it is slightly active to inactive against leukemias. On a weight basis, rapamycin was less active than 5-fluorouracil, cyclophosphamide and adriamycin, but rapamycin's maximal activity against Colon 38 tumor was similar to that of 5-fluorouracil and cyclophosphamide. Its activity was such that it significantly inhibited tumor growth at any stage of development. In the active dose range, rapamycin appeared less toxic than the other drugs. In the Colon 38 tumor model, rapamycin at a given dose exhibited the same activity when administered ip, iv, im and sc; upon oral administration, its activity was reduced but not abolished. Rapamycin was compatible with 5-fluorouracil and cyclophosphamide. The sequential treatment 5-fluorouracil-rapamycin-cyclophosphamide was superior to the sequence 5-fluorouracil-adriamycin-cyclophosphamide in protecting Colon 38 tumor-bearing mice. 29-Demethoxyrapamycin exerted only marginal activity against P388 lymphocytic leukemia; it was inactive against B16 melanocarcinoma and Colon 38 solid tumor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|